Stay updated on Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page
- CheckyesterdayChange DetectedLocations are consolidated into a central Locations section listing study sites across multiple states and Ontario. Individual state location subsections were removed and the page version updated to v3.3.3.SummaryDifference1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedA note was added that PubMed publications are automatically filled from PubMed and may not be about the study, and the revision version was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check36 days agoChange DetectedRemoved the boilerplate notice about potential delays due to a lapse in government funding from the page; core study details, eligibility criteria, locations, and study design remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check51 days agoChange DetectedNo substantive changes detected; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check80 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference2%

- Check87 days agoChange Detected- Page now shows that results have been submitted and are available. - Revision updated from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Nivolumab in Endometrial Cancer Clinical Trial page.